Skip to main content


Chronic Lymphocytic Leukemia

Featured

News
A recent real-world study compared HCRU and costs associated with first-line ibrutinib monotherapy vs bendamustine plus rituximab for patients with CLL.
Videos
Tara Graff, DO, explains how the introduction of acalabrutinib has impacted the treatment of CLL.
Videos
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in…
News
Acalabrutinib demonstrated favorable PFS and OS compared with standard first-line treatments for CLL, according to a…
Quiz
True or False: First-line acalaburitnib plus obinutuzmumab prolongs progression-free survival compared to ibrutinib-…
Back to Top